Acumen Pharma's ACU193 Shows Potential in Alzheimer's Trial; Bullish View for EnerSys
- July 16th, 2023
- 348 views
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) announced positive topline results from the Phase 1 INTERCEPT-AD trial evaluating the company's ACU193, a clinical-stage antibody therapy targeting amyloid beta oligomers (AβOs) in early Alzheimer's disease (AD).
The trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193. Remarkably, higher dose cohorts showed rapid and significant amyloid plaque reduction, paving the way for potential monthly dosing.
On Friday, $ABOS closed at $6.28, reflecting an increase of $0.16 (+2.61%).
In other news, EnerSys (NYSE: ENS), a leading provider of stored energy solutions for industrial applications, received coverage initiation from CL King with a Buy rating and a price target of $137.
Considering $ENS closed at $110.68 on Friday, the suggested price target suggests a potential upside of $26.32 or approximately 23.77%, according to the investment firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login